Monoclonal antibody | |
---|---|
Type | ? |
Legal status | |
Legal status |
|
Temelimab (also known as GNbAC1[1]) is an experimental monoclonal antibody drug for immune system conditions that neutralizes the human endogenous retrovirus envelope protein HERV-W.[2][3] It has been studied for multiple sclerosis up to phase 2b, where it was found to be safe and to reduce brain lesions.[1] As of 2023, it is also being studied for cognitive impairment in long COVID.[4]